The new slate of directors for Olympus Corp. (TYO:7733) is already drawing fire from foreign investors in the endoscopy giant, after its entire board resigned en masse over a $1.7 billion accounting scandal that’s slashed its valuation by about 50% since October.
CerviLenz
FDA clears Philips combination PET/MR scanner | Regulatory Roundup
Philips Ingenuity Scanner
Philips Healthcare (NYSE:PHG) landed 510(k) clearance from the FDA to market its Ingenuity whole-body PET/MR imaging system in the U.S.
The scanner performs both PET and magnetic resonance imaging scans, allowing doctors to acquire images at a significantly lower radiation dose than traditional PET/computer tomography scanners, which use x-rays to make images.
Diabetes: Stratatech lands $4.6 million to study antimicrobial skin graft for diabetic foot ulcers | Funding Roundup
Stratatech Corp. won a $4.6 million grant to run a clinical trial from the National Institute of Diabetes & Digestive & Kidney Diseases.
The funds will support the first human study of Stratatech’s ExpressGraft Antimicrobial genetically engineered living skin substitute as a therapy for diabetic foot ulcers.
Boston University lands $13.6M to study cancer detection tools | Funding Roundup
Boston University School of Medicine landed a $13.6 million grant from the U.S. Defense Dept. lung cancer research program to study technologies focused on the early detection of lung cancer.
The five-year study, the Detecting Early Lung Cancer Among Military Personnel consortium, will focus on veterans and active military personnel at number of military hospitals and VA medical centers across the country.
Smoking rates are 50 percent higher in military populations than civilian populations and veterans are between 25 and 75 percent more likely to develop lung cancer than non-veterans, according to BU.
CerviLenz taps its first CFO/COO
By Mary Vanac
Medical device start-up CerviLenz Inc. appointed its first CFO/COO: Federica “Freddi” O’Brien, a certified public accountant who spent the last decade working with bioscience companies.
CerviLenz plus progesterone could halve preterm birth risk
By Mary Vanac
CerviLenz is a simple, low-tech medical device that prompts a “why didn’t I think of that?” response from many obstetricians.
Yet the device that quickly, accurately and inexpensively measures a pregnant woman’s cervix could help answer the $26 billion-a-year problem of preterm birth in the United States.
CerviLenz aims to lower preterm birth rate
By Mary Vanac
A disposable device made by Chagrin Falls, Ohio-based CerviLenz Inc. aims to take the guesswork out of determining the risk of premature birth.